We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


31 October 2005 By Robert Cyran

The Swiss drug group s 42% stake in the US vaccine maker gave it unbeatable leverage in takeover negotiations. Chiron s board had little choice but to accept a slightly sweetened second offer. This leaves plenty of honey for Novartis.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)